WCM
GILD icon

Warburton Capital Management’s Gilead Sciences GILD Stock Holding History

Warburton Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
1,740
-144
-8% -$19K 0.09% 67
2026
Q1 		$267K Buy
1,884
+158
+9% +$22.1K 0.13% 49
2025
Q4 		$211K Buy
+1,726
New +$210K 0.12% 57

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Warburton Capital Management's GILD Position: Q2 2026 in Review

Warburton Capital Management reduced its Gilead Sciences (GILD) stake by 7.6% in Q2 2026, selling an estimated $19K and leaving 1,740 shares worth $219K. The position accounts for 0.09% of the portfolio, ranked #67.

Warburton Capital Management first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $267K in Q1 2026. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Warburton Capital Management held 1,740 shares of Gilead Sciences worth $219K as of Q2 2026.
  • Warburton Capital Management sold 144 Gilead Sciences shares in Q2 2026, an estimated $19K.
  • Gilead Sciences made up 0.09% of Warburton Capital Management's portfolio in Q2 2026, its #67 holding.
  • Warburton Capital Management first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Warburton Capital Management's Gilead Sciences position peaked at $267K in Q1 2026.
  • 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Warburton Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.